[artículo] 
inEuropean Neuropsychopharmacology > Año 2015 - Vol. 25 - No.1 (Enero) . - pp. 38-50

Título :	Curcumin and major depression : A randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change
Tipo de documento:	texto impreso
Autores:	Adrian L. Lopresti, Autor ; Michaël H.J. Maes, Autor ; Marcus J.M. Meddens, Autor
Fecha de publicación:	2021
Artículo en la página:	pp. 38-50
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Depresión, Curcumina, Biomarcadores, Cúrcuma, Ensayo clínico
Resumen:	A recent randomised, double-blind, placebo controlled study conducted by our research group, provided partial support for the efficacy of supplementation with a patented curcumin extract (500 mg, twice daily) for 8 weeks in reducing depressive symptoms in people with major depressive disorder.
Link:	./index.php?lvl=notice_display&id=26843

[artículo] Curcumin and major depression : A randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change [texto impreso] / Adrian L. Lopresti, Autor ; Michaël H.J. Maes, Autor ; Marcus J.M. Meddens, Autor . - 2021 . - pp. 38-50.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2015 - Vol. 25 - No.1 (Enero) . - pp. 38-50

Palabras clave:	Depresión, Curcumina, Biomarcadores, Cúrcuma, Ensayo clínico
Resumen:	A recent randomised, double-blind, placebo controlled study conducted by our research group, provided partial support for the efficacy of supplementation with a patented curcumin extract (500 mg, twice daily) for 8 weeks in reducing depressive symptoms in people with major depressive disorder.
Link:	./index.php?lvl=notice_display&id=26843